Last reviewed · How we verify
Oxycodone and acetaminophen combination treatment
Oxycodone binds to opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
Oxycodone binds to opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Moderate to severe acute pain, Post-operative pain management.
At a glance
| Generic name | Oxycodone and acetaminophen combination treatment |
|---|---|
| Sponsor | Barrie Urology Associates |
| Drug class | Opioid analgesic combination |
| Target | Mu opioid receptor (oxycodone); cyclooxygenase enzymes (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oxycodone is a semi-synthetic opioid agonist that acts on mu, delta, and kappa opioid receptors in the central nervous system to modulate pain signals. Acetaminophen works through inhibition of cyclooxygenase (COX) enzymes and prostaglandin production, providing complementary analgesia. The combination allows for enhanced pain relief at lower individual doses of each component.
Approved indications
- Moderate to severe acute pain
- Post-operative pain management
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Vomiting
- Pruritus
- Respiratory depression
Key clinical trials
- Opioid Drug Interaction Study (PHASE1, PHASE2)
- IV vs Oral Acetaminophen in Spine Fusion Perioperative Care (PHASE4)
- ICE-T Pain Regimen for Total Laparoscopic Hysterectomy (PHASE4)
- Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure (PHASE2)
- Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer (PHASE1)
- Narcotic vs. Non-narcotic Pain Study Protocol (PHASE4)
- Pain Management in Head and Neck Surgery Patients (PHASE4)
- Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: